Magnevist Articles
Bayer hit by charges and falling material science sales in 1st qtr, but pharma division doing well
29 April 2009
USA's HealthTrust signs 3-year renewal for Bayer's Magnevist
19 November 2007
Premier extends deal with Bayer for contrast media
30 July 2007
FDA call for warning on contrast agents
4 June 2007
Berlex awarded HPG Magnevist contract
15 August 2005
Schering AG 1st-half profits leap 23%
1 August 2005
Berlex, Premier in new MRI contrast deal
9 May 2005
Net income up 24% at Schering AG as Betaferon sales stay strong
11 February 2002
Net income up 23% at Schering AG as Betaferon sales stay strong
9 November 2001
Schering AG 1st-qtr net income rises 19%
25 April 2001
Schering AG gets first approval for Resovist
29 March 2001
Good 1st-half sales and profits at Schering AG
28 July 2000
Flat Interim Results From Schering AG
14 August 1995
Currency Impacts Schering AG's Earnings Growth
15 August 1994
GOOD 1993 FIRST HALF FOR SCHERING AG
16 August 1993
PENDING APPLICATIONS IN US CONTINUE TO DWINDLE
19 July 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
SIGNIFICANT MOVES BY PHARMA COS IN FT 500
1 March 1993
AGROCHEMICALS PULL SCHERING DOWN
22 February 1993
HAFSLUND NYCOMED DOWNGRADED
7 December 1992
CONTRAST MEDIA MARKET SLOWDOWN EXPLAINED
7 December 1992
B-MS' PROHANCE APPROVED IN USA
7 December 1992
1991 "BETTER THAN EXPECTED" AT SCHERING
22 June 1992
Showing 1-29 of 29 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
